Therapeutic Pipeline
Pathway-Specific
Genetic Medicines
Our Development Pipeline
PROGRAM
INDICATION
PHASE 1
PRECLINICAL
DISCOVERY
NVC-001A
LMNA DCM
NVC-002
UNDISCLOSED
ADDITIONAL
PROGRAMS
UNDISCLOSED
NVC-001B
UNDISCLOSED
LMNA Dilated Cardiomyopathy
Nuevocor’s lead program NVC-001 treat patients suffering lamin-related dilated cardiomyopathy by addressing the biomechanical root cause of disease. Dilated cardiomyopathy is a common cause of heart failure, characterized by enlargement of the left ventricle and a reduction in the ability of the heart to pump blood. Lamin-related dilated cardiomyopathy is among the top 3 most common causes of genetic dilated cardiomyopathy and has the worst prognosis of all dilated cardiomyopathies, making it a serious and aggressive disease. Today, other than receiving a cardiac transplant, there are no effective treatments available.